Matches in SemOpenAlex for { <https://semopenalex.org/work/W3216529503> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W3216529503 endingPage "vi158" @default.
- W3216529503 startingPage "vi157" @default.
- W3216529503 abstract "Abstract INTRODUCTION Standard of care for glioblastoma consists of surgery, followed by combined chemoradiation and adjuvant chemotherapy, as per the seminal EORTC study from 2005. Clinical trial patients, being a population selected for functional status, hepatic function, renal function, and lack of other malignancies, may have improved outcome over the general treated population. METHOD Single center retrospective analysis of status as a clinical trial patient in the upfront setting and other clinical factors/biomarkers, analyzed for correlation with outcomes (PFS/OS) in IDH-wildtype glioblastomas. RESULTS 82 patients with IDH-wildtype glioblastoma were identified between 2014 and 2020, treated with standard of care or with an upfront clinical study (43% women; median age 66 years, range 35-91 years of age). 22 patients (27%) were treated with upfront clinical study. Status as a patient treated in an upfront clinical study did not correlate with outcome (hazard ratio HR PFS 0.99, CI 0.57-1.7, p=0.97; HR OS 1.09, CI 0.56-2.1, p=0.81). Frontal lobe was most frequently involved (n=36, 44%), followed by parietal lobe (n=33, 40%). Age was not a strong predictor of survival (R2 0.01). No statistically significant correlation was observed between outcome and laterality or location. MGMT promoter methylation was associated with improved PFS (HR 0.56, CI 0.33-0.94, p=0.03) and OS (HR 0.40, CI 0.19-0.85, p=0.02), with mPFS 6 months vs 9 months and mOS 16 months vs 20 months (unmethylated vs methylated respectively). CONCLUSION In this retrospective cohort of IDH-wildtype glioblastomas, age, tumor laterality, and tumor location were not significant predictors of outcome. MGMT promoter methylation predicted for superior PFS/OS. Patient selection for clinical studies are influenced by entry criteria, however at least in this retrospective review, status as a clinical study patient in the upfront setting did not correlate with outcome compared to patients treated with upfront standard of care." @default.
- W3216529503 created "2021-12-06" @default.
- W3216529503 creator A5001958837 @default.
- W3216529503 creator A5012877310 @default.
- W3216529503 creator A5015328297 @default.
- W3216529503 creator A5030819228 @default.
- W3216529503 creator A5050534702 @default.
- W3216529503 creator A5057541817 @default.
- W3216529503 creator A5080062627 @default.
- W3216529503 creator A5085091575 @default.
- W3216529503 creator A5087754052 @default.
- W3216529503 date "2021-11-02" @default.
- W3216529503 modified "2023-09-25" @default.
- W3216529503 title "NCOG-27. STATUS AS A CLINICAL TRIAL PARTICIPANT AND OUTCOME IN IDH-WILDTYPE GLIOBLASTOMA" @default.
- W3216529503 doi "https://doi.org/10.1093/neuonc/noab196.618" @default.
- W3216529503 hasPublicationYear "2021" @default.
- W3216529503 type Work @default.
- W3216529503 sameAs 3216529503 @default.
- W3216529503 citedByCount "0" @default.
- W3216529503 crossrefType "journal-article" @default.
- W3216529503 hasAuthorship W3216529503A5001958837 @default.
- W3216529503 hasAuthorship W3216529503A5012877310 @default.
- W3216529503 hasAuthorship W3216529503A5015328297 @default.
- W3216529503 hasAuthorship W3216529503A5030819228 @default.
- W3216529503 hasAuthorship W3216529503A5050534702 @default.
- W3216529503 hasAuthorship W3216529503A5057541817 @default.
- W3216529503 hasAuthorship W3216529503A5080062627 @default.
- W3216529503 hasAuthorship W3216529503A5085091575 @default.
- W3216529503 hasAuthorship W3216529503A5087754052 @default.
- W3216529503 hasBestOaLocation W32165295031 @default.
- W3216529503 hasConcept C126322002 @default.
- W3216529503 hasConcept C141071460 @default.
- W3216529503 hasConcept C143998085 @default.
- W3216529503 hasConcept C207103383 @default.
- W3216529503 hasConcept C2776694085 @default.
- W3216529503 hasConcept C2780073493 @default.
- W3216529503 hasConcept C2780739268 @default.
- W3216529503 hasConcept C2908647359 @default.
- W3216529503 hasConcept C44249647 @default.
- W3216529503 hasConcept C535046627 @default.
- W3216529503 hasConcept C71924100 @default.
- W3216529503 hasConcept C99454951 @default.
- W3216529503 hasConceptScore W3216529503C126322002 @default.
- W3216529503 hasConceptScore W3216529503C141071460 @default.
- W3216529503 hasConceptScore W3216529503C143998085 @default.
- W3216529503 hasConceptScore W3216529503C207103383 @default.
- W3216529503 hasConceptScore W3216529503C2776694085 @default.
- W3216529503 hasConceptScore W3216529503C2780073493 @default.
- W3216529503 hasConceptScore W3216529503C2780739268 @default.
- W3216529503 hasConceptScore W3216529503C2908647359 @default.
- W3216529503 hasConceptScore W3216529503C44249647 @default.
- W3216529503 hasConceptScore W3216529503C535046627 @default.
- W3216529503 hasConceptScore W3216529503C71924100 @default.
- W3216529503 hasConceptScore W3216529503C99454951 @default.
- W3216529503 hasIssue "Supplement_6" @default.
- W3216529503 hasLocation W32165295031 @default.
- W3216529503 hasLocation W32165295032 @default.
- W3216529503 hasOpenAccess W3216529503 @default.
- W3216529503 hasPrimaryLocation W32165295031 @default.
- W3216529503 hasRelatedWork W2018515503 @default.
- W3216529503 hasRelatedWork W2139647583 @default.
- W3216529503 hasRelatedWork W2185481272 @default.
- W3216529503 hasRelatedWork W2738884707 @default.
- W3216529503 hasRelatedWork W3004966710 @default.
- W3216529503 hasRelatedWork W4205113611 @default.
- W3216529503 hasRelatedWork W4281727781 @default.
- W3216529503 hasRelatedWork W4294938756 @default.
- W3216529503 hasRelatedWork W4305082178 @default.
- W3216529503 hasRelatedWork W4362521439 @default.
- W3216529503 hasVolume "23" @default.
- W3216529503 isParatext "false" @default.
- W3216529503 isRetracted "false" @default.
- W3216529503 magId "3216529503" @default.
- W3216529503 workType "article" @default.